Phosphodiesterase 4 inhibitor combined with secukinumab relieves clinical symptoms in patients with psoriasis via regulating p38MAPK activation and the immune response inflammation
Secukinumab along with phosphodiesterase 4 inhibitors reduces p38MAPK activation, and improves immune response, inflammation, and clinical symptoms in patients with psoriasis.
Authors
- Zihan Zhou (ORCID: https://orcid.org/0000-0002-0285-702X)
- Li Zhang (ORCID: https://orcid.org/0000-0003-1125-1991)
- Min Zhao (ORCID: https://orcid.org/0000-0003-0386-7008)
- Changzheng Wei (ORCID: https://orcid.org/0000-0003-0467-2253)
- Xingxing Wang (ORCID: https://orcid.org/0000-0001-5030-3817)
- Qian Zhang (ORCID: https://orcid.org/0000-0003-1036-3940)
- Hong Zhao
Institutions
- Wuhan University (CN)
- Fifth Hospital In Wuhan (CN)
Publication Details
- Journal
- African Health Sciences
- Published
- 2025-05-09
- DOI
- https://doi.org/10.4314/ahs.v25i1.35
- Primary Topic
- Phosphodiesterase function and regulation
- Type
- article
- Field-Weighted Citation Impact
- 0.00